JPWO2020002353A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020002353A5 JPWO2020002353A5 JP2020571767A JP2020571767A JPWO2020002353A5 JP WO2020002353 A5 JPWO2020002353 A5 JP WO2020002353A5 JP 2020571767 A JP2020571767 A JP 2020571767A JP 2020571767 A JP2020571767 A JP 2020571767A JP WO2020002353 A5 JPWO2020002353 A5 JP WO2020002353A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- weight
- pharmaceutical composition
- dispersion
- disaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 33
- 239000006185 dispersion Substances 0.000 claims 22
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 229930105110 Cyclosporin A Natural products 0.000 claims 18
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 18
- 108010036949 Cyclosporine Proteins 0.000 claims 18
- 239000002502 liposome Substances 0.000 claims 16
- 239000007788 liquid Substances 0.000 claims 14
- 150000002016 disaccharides Chemical class 0.000 claims 13
- 239000000126 substance Substances 0.000 claims 12
- 229930006000 Sucrose Natural products 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 150000003904 phospholipids Chemical class 0.000 claims 10
- 229960004793 sucrose Drugs 0.000 claims 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 9
- 239000008365 aqueous carrier Substances 0.000 claims 9
- 235000013681 dietary sucrose Nutrition 0.000 claims 9
- 239000008101 lactose Substances 0.000 claims 9
- 239000002736 nonionic surfactant Substances 0.000 claims 9
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 8
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 8
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 8
- 229960001265 ciclosporin Drugs 0.000 claims 7
- 239000000243 solution Substances 0.000 claims 7
- 239000008137 solubility enhancer Substances 0.000 claims 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 3
- 238000002296 dynamic light scattering Methods 0.000 claims 3
- 239000000787 lecithin Substances 0.000 claims 3
- 235000010445 lecithin Nutrition 0.000 claims 3
- 229940067606 lecithin Drugs 0.000 claims 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 238000004108 freeze drying Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 230000000414 obstructive effect Effects 0.000 claims 2
- 229920000136 polysorbate Polymers 0.000 claims 2
- 229950008882 polysorbate Drugs 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 206010051604 Lung transplant rejection Diseases 0.000 claims 1
- 206010029888 Obliterative bronchiolitis Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 238000000889 atomisation Methods 0.000 claims 1
- 201000003848 bronchiolitis obliterans Diseases 0.000 claims 1
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- -1 disaccharide disaccharide Chemical class 0.000 claims 1
- 125000000600 disaccharide group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229940042880 natural phospholipid Drugs 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000008347 soybean phospholipid Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 125000005314 unsaturated fatty acid group Chemical group 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18180177 | 2018-06-27 | ||
| EP18180177.0 | 2018-06-27 | ||
| PCT/EP2019/066875 WO2020002353A1 (en) | 2018-06-27 | 2019-06-25 | Pharmaceutical compositions in lyophilized form |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021528450A JP2021528450A (ja) | 2021-10-21 |
| JPWO2020002353A5 true JPWO2020002353A5 (https=) | 2022-06-28 |
| JP2021528450A5 JP2021528450A5 (https=) | 2022-06-28 |
| JP7401471B2 JP7401471B2 (ja) | 2023-12-19 |
Family
ID=62814888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020571767A Active JP7401471B2 (ja) | 2018-06-27 | 2019-06-25 | 凍結乾燥形態の医薬組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210244664A1 (https=) |
| EP (1) | EP3813788A1 (https=) |
| JP (1) | JP7401471B2 (https=) |
| CN (1) | CN113038930A (https=) |
| AU (1) | AU2019295027B2 (https=) |
| BR (1) | BR112020026629A2 (https=) |
| CO (1) | CO2021000223A2 (https=) |
| EA (1) | EA202092893A1 (https=) |
| IL (1) | IL279760B2 (https=) |
| MX (1) | MX2020013831A (https=) |
| WO (1) | WO2020002353A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025204688A1 (ja) * | 2024-03-26 | 2025-10-02 | 株式会社ダイセル | リン脂質膜保護用液体組成物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4857319A (en) * | 1985-01-11 | 1989-08-15 | The Regents Of The University Of California | Method for preserving liposomes |
| EP0208764A4 (en) | 1985-01-11 | 1987-10-08 | Univ California | METHOD FOR PRESERVING LIPOSOMES. |
| US4963362A (en) | 1987-08-07 | 1990-10-16 | Regents Of The University Of Minnesota | Freeze-dried liposome mixture containing cyclosporin |
| DE69211691T2 (de) | 1991-04-19 | 1997-01-16 | Nexstar Pharmaceuticals Inc., Boulder, Col. | Pharmazeutische formulierung und pharmazeutisches verfahren |
| WO1996040064A1 (en) | 1995-06-07 | 1996-12-19 | Nexstar Pharmaceuticals, Inc. | Liposomal cyclosporin formulations as agents for immunosuppression and multiple drug resistant indications |
| TW497974B (en) * | 1996-07-03 | 2002-08-11 | Res Dev Foundation | High dose liposomal aerosol formulations |
| US5958378A (en) * | 1996-07-03 | 1999-09-28 | Research Development Foundation | High dose liposomal aerosol formulations containing cyclosporin A or budesonide |
| IT1289938B1 (it) * | 1997-02-20 | 1998-10-19 | Angelini Ricerche Spa | Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e |
| AU2003237863A1 (en) | 2002-05-20 | 2003-12-12 | Research Development Foundation | Aerosol drug inhibition of lung metastases |
| EP1687635A2 (en) * | 2003-11-26 | 2006-08-09 | Applera Corporation | Ligand-containing micelles and uses thereof |
| EP1750671B1 (en) * | 2004-06-03 | 2008-10-15 | Bracco Research S.A. | Liposomal assembly for therapeutic and/or diagnostic use |
| DE102006051512A1 (de) * | 2005-12-06 | 2007-06-14 | Pari GmbH Spezialisten für effektive Inhalation | Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin |
| CA2631243A1 (en) * | 2005-12-08 | 2007-06-14 | Wyeth | Liposomal compositions |
| EP1797895A1 (en) * | 2005-12-16 | 2007-06-20 | Pevion Biotech Ltd. | An adjuvant system comprising virosomes and liposomes |
| US20110070294A1 (en) * | 2009-09-23 | 2011-03-24 | Javeri Indu | Methods for the Administration of Drugs Using Liposomes |
| US20140127288A1 (en) * | 2011-05-17 | 2014-05-08 | Mitsubishi Gas Chemical Company, Inc. | Liposome containing pyrroloquinoline quinone and sugar |
| EP3069711A1 (en) * | 2015-03-16 | 2016-09-21 | PARI Pharma GmbH | Cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection |
-
2019
- 2019-06-25 IL IL279760A patent/IL279760B2/en unknown
- 2019-06-25 US US17/251,223 patent/US20210244664A1/en not_active Abandoned
- 2019-06-25 EA EA202092893A patent/EA202092893A1/ru unknown
- 2019-06-25 CN CN201980043201.0A patent/CN113038930A/zh active Pending
- 2019-06-25 WO PCT/EP2019/066875 patent/WO2020002353A1/en not_active Ceased
- 2019-06-25 MX MX2020013831A patent/MX2020013831A/es unknown
- 2019-06-25 AU AU2019295027A patent/AU2019295027B2/en active Active
- 2019-06-25 JP JP2020571767A patent/JP7401471B2/ja active Active
- 2019-06-25 BR BR112020026629-9A patent/BR112020026629A2/pt unknown
- 2019-06-25 EP EP19732066.6A patent/EP3813788A1/en active Pending
-
2021
- 2021-01-14 CO CONC2021/0000223A patent/CO2021000223A2/es unknown
-
2023
- 2023-05-16 US US18/317,940 patent/US20230301914A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rajera et al. | Niosomes: a controlled and novel drug delivery system | |
| JP2958774B2 (ja) | アンホテリシンｂリポソームの改良調整法 | |
| CN107427482A (zh) | 凝血酸的多囊脂质体制剂 | |
| JPH0534334B2 (https=) | ||
| US20110256213A1 (en) | Phospholipid micellar and liposomal compositions and uses thereof | |
| JP2022078013A (ja) | エラスターゼ阻害活性を有するベータヘアピンペプチド模倣体及びそのエアロゾル剤形 | |
| WO2017097196A1 (zh) | 脂质体的制备方法 | |
| CN103622924B (zh) | 一种多西他赛脂质体及其制备方法 | |
| US20100098753A1 (en) | Prophylactic and/or therapeutic agent for cardiac infarction | |
| JPWO2020002353A5 (https=) | ||
| JP2021528450A5 (https=) | ||
| Chiller et al. | Treatment strategies for Aspergillus infections | |
| JP7401471B2 (ja) | 凍結乾燥形態の医薬組成物 | |
| WO2011084610A1 (en) | Liposomes for preventing the spread of hiv | |
| TWI630000B (zh) | 安定性高藥物劑載之奈米載劑，其製備方法及其用途 | |
| CA3104445C (en) | Pharmaceutical compositions in lyophilized form | |
| JP7726884B2 (ja) | 吸入可能な免疫抑制活性成分を含む分散液の調製のためのプロセス | |
| CA3161686C (en) | Process for the preparation of dispersions comprising inhalable immunosuppressive active ingredients | |
| NR et al. | TARGETED DRUG DELIVERY IN GASTROESOPHAGEAL REFLUX DISEASE: THE ROLE OF MUCOADHESIVE AND LIPOSOME SYSTEMS | |
| Ricchetti et al. | Effect of local antifungal treatment on nasal polyposis | |
| EA048772B1 (ru) | Фармацевтические композиции в лиофилизированной форме | |
| Georgiev | Treatment and Developmental Therapeutics in Aspergillosis. 1. Amphotericin B and Its Derivatives: 1. Amphotericin B and Its Derivatives | |
| KR20250059610A (ko) | 흡입형 마이크로겔 약물전달체 및 이를 포함하는 폐섬유증 치료용 약학조성물 | |
| EA046086B1 (ru) | Способ получения дисперсий, содержащих ингаляционные иммуносупрессивные активные ингредиенты | |
| Svartengren et al. | Medicinal particles |